Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: MenQuadfi (Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid) — Sanofi Winthrop Industrie
EMA has authorised MenQuadfi, a meningococcal vaccine combination covering groups A, C, W-135, and Y (tetanus toxoid-conjugated), for mening…
-
EMA approval · 2026-07-10EMA Authorised: Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) — GSK Vaccines S.r.l.
The European Medicines Agency has authorised Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine by GSK Vaccines S.r.l., for i…
-
EMA approval · 2026-03-24EMA Authorised: MenQuadfi (Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid) — Sanofi Winthrop Industrie
The European Medicines Agency authorised MenQuadfi, a tetravalent meningococcal conjugate vaccine (serogroups A, C, W-135 and Y) manufacture…
-
EMA approval · 2025-12-17EMA Authorised: Trumenba (Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B) — Pfizer Europe MA EEIG
The EMA has authorised Trumenba, a vaccine against meningococcal disease caused by Neisseria meningitidis serogroup B, for use in Europe.
-
EMA approval · 2025-10-14EMA Authorised: Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) — GSK Vaccines S.r.l.
EMA authorised Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine, for immunization against meningococcal disease. The decisi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-08FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Rifadin IV (rifampin) submitted by Sanofi-Aventis U.S. LLC. This action covers the intraveno…
-
EMA approval · 2025-08-01EMA Authorised: Bexsero (outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254);recombinant Neisseria meningitidis group B fHbp fusion protein;recombinant Neisseria meningitidis group B NadA protein;recombinant Neisseria meningitidis group B NHBA fusion protein) — GSK Vaccines S.r.l.
The European Medicines Agency authorised Bexsero, a meningococcal group B vaccine produced by GSK Vaccines S.r.l., for use in Europe. The va…
-
EMA approval · 2025-02-13EMA Authorised: Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid) — Pfizer Europe MA EEIG
The EMA authorised Nimenrix, a quadrivalent meningococcal conjugate vaccine, for prevention of invasive meningococcal disease caused by sero…
-
FDA approval · 2023-08-16FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application to add an intravenous formulation of rifampin (RIFADIN IV).
-
FDA approval · 2023-08-16FDA Approved: RIFAMPIN — Supplemental Application (EPIC PHARMA, LLC)
FDA approved a supplemental application for Rifampin from Epic Pharma, LLC. The approval likely updates labeling or indications for the prod…
-
FDA approval · 2022-01-29FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for the IV formulation Rifadin (rifampin) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2022-01-19FDA Approved: RIFAMPIN — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Rifampin from Chartwell RX, LLC under an ANDA. This confirms approval of a generic Rifampin prod…
-
FDA approval · 2021-09-14FDA Approved: RIFAMPIN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Rifampin under the ANDA. The approval indicates changes to the Rifampin pro…
-
FDA approval · 2021-09-13FDA Approved: RIFAMPIN — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Rifampin (RIFAMPIN) submitted by Chartwell RX, LLC under ANDA065390.
-
FDA approval · 2021-09-13FDA Approved: RIFAMPIN — Supplemental Application (EPIC PHARMA, LLC)
The FDA approved a supplemental application for Rifampin from Epic Pharma, LLC. The action pertains to changes under the Rifampin ANDA 06415…
-
FDA approval · 2020-09-02FDA Approved: RIFAMPIN — Supplemental Application (Chartwell RX, LLC)
FDA approves Chartwell RX, LLC's supplemental application for rifampin (RIFAMPIN).
-
FDA approval · 2014-08-21FDA Approved: RIFAMPIN — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's generic rifampin (RIFAMPIN) under an Original Application (ANDA), expanding access to this antibiotic…
-
FDA approval · 2010-11-10FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Rifadin IV (rifampin) by Sanofi-Aventis U.S. LLC to support its intravenous formulation.
-
FDA approval · 2008-05-22FDA Approved: RIFAMPIN — Original Application (Mylan Institutional LLC)
FDA approved an Original Application for rifampin from Mylan Institutional LLC, enabling a generic rifampin product. This action approves th…
-
FDA approval · 2008-03-28FDA Approved: RIFAMPIN — Original Application (Chartwell RX, LLC)
FDA approved an Original Application (ANDA) for rifampin submitted by Chartwell RX, LLC. This marks approval of a generic rifampin product.